Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

ABMT Recommended for Relapsed Hodgkin's Disease, But Better Overall Survival Not Yet Proved

April 1, 1996
News
Article
OncologyONCOLOGY Vol 10 No 4
Volume 10
Issue 4

The bulk of available evidence has made a persuasive case for early bone marrow transplantation as the treatment of choice for patients with relapsed Hodgkin's disease, Philip J. Bierman, MD, said at a lymphoma conference sponsored by the University of Texas M.D. Anderson Cancer Center.

The bulk of available evidence has made a persuasive case forearly bone marrow transplantation as the treatment of choice forpatients with relapsed Hodgkin's disease, Philip J. Bierman, MD,said at a lymphoma conference sponsored by the University of TexasM.D. Anderson Cancer Center.

However, Dr. Bierman's confidence in autologous bone marrow transplantation(ABMT) hinges on an important caveat: The procedure has not beenshown to improve overall survival.

"In most clinical situations, the failure-free survival followinghigh-dose therapy with ABMT for Hodgkin's disease is superiorto conventional dose salvage chemotherapy," he said, "buttransplantation's ability to improve overall survival has notbeen demonstrated. However, at our institution, we recommend transplantationfor any patient who has relapsed after chemotherapy."

To date, only a single randomized trial has compared ABMT withconventional salvage therapy for relapsed Hodg-kin's disease.This trial was conducted by the British National Lymphoma Investigationand was stopped early after accrual of only 40 patients due toimproved outcome in the patients receiving high-dose therapy,said Dr. Bierman, associate professor of medicine, Universityof Nebraska.

Conventional Salvage Chemo

Conventional salvage chemotherapy has produced unspectacular resultsin a number of studies, Dr. Bierman said. National Cancer Instituteinvestigators have reported 24% long-term survival among patientswho had initial remissions of 12 months or more after MOPP therapyand were treated with MOPP-based therapy in relapse. Among patientswith shorter remissions, only about 10% survived long term, Dr.Bierman said.

The best reported results have come from an Italian study showinga 46% long-term failure-free survival in patients who had longinitial remissions and then were treated at relapse with MOPP,ABVD, or a combination of the two. However, Dr. Bierman notedthat the study excluded patients who developed secondary leukemiasor who had cardiac or pulmonary deaths.

In general, other studies of conventional salvage chemotherapyhave found long-term failure-free survival in no more than 25%to 30% of patients, with much worse results in patients with shortinitial remissions or induction failure.

Radiation Results

Good results have been achieved with radiation therapy, but inrelatively small numbers of patients, some of whom also receivedchemotherapy. In five published studies with about 100 patientstotal, complete responses rates have ranged as high as 92%. Disease-freesurvival at 5 years has ranged between 24% and 50%.

The best results have occurred in patients with initial remissionsexceeding a year and in those without extranodal disease. "Ifyou wanted to argue, you could say that the disease-free survivalresults with radiation therapy have been as good as any salvagetherapy or, in fact, as good as bone marrow transplantation,"Dr. Bierman said.

Survival With ABMT

Studies of high-dose salvage therapy with ABMT or peripheral bloodstem cell support have shown encouraging results, he said. Atthe University of Nebraska, 5-year failure-free survival is 40%among 85 patients. British investigators have reported a 47% long-termfailure-free survival, including 57% in patients with long initialremissions and 41% in patients with short initial remissions.

Stanford researchers have reported a 60% progression-free survivalin patients treated with ABMT after relapse or failure to achieveremission, compared with 30% for another group treated with conventionalchemotherapy. Overall survival favored the transplant group (55%vs 46%) but did not reach statistical significance, Dr. Biermansaid.

The best results have come from a Vancouver study that showedan 80% to 85% failure-free survival in patients with long initialremissions. Overall, two thirds of the 57 patients remained failurefree at 7 years. "These results are clearly better than anythingthat has ever been reported in the literature," Dr. Biermancommented.

Transplantation has shown promise in Hodgkin's disease patientswho have induction failure, as well as in patients with relapseddisease, Dr. Bierman said at the M.D. Anderson lymphoma symposium(see story above).

At the University of Nebraska, about one fourth of 44 such patientshave achieved long-term remission. Dr. Bierman noted that thepatients "spanned the gamut from those with progressive diseaseto those with good partial responses initially."

Canadian investigators recently reported that about half of 30induction failures had durable failure-free survival after bonemarrow or peripheral stem cell transplantation (Blood 86:451,1995).

"Without any prospective trials or comparative studies, Iwould submit that if a patient is an induction failure, the patientshould proceed to high-dose therapy with autologous transplantation,Dr. Bierman said.

Articles in this issue

Radiosurgery Plus Sensitizer Tested for Brain Tumors
Update: Mortality Attributable to HIV Infection Among Persons Age 25 to 44 Years--United States, 1994
New Sequential Dosing Regimen Shows Promise in Node-Positive Breast Cancer
Combination Therapy for Rare Dermal Sarcoma Effective, Avoids Radical Surgery
Regular NSAID Use Appears to Reduce Breast Cancer Severity
Deaths from Melanoma--United States, 1973-1992
Survivors of Childhood Cancer Face Other Medical Risks As Adults
Transition to Managed Care Will Bring Changes for Oncologists, Need for Guidelines, Says ACCC Panel
Post-Transplantation Complications of Unrelated Bone Marrow
Intensified VICE Regimen May Improve SCLC Survival
Fox Chase/Stanford Study: Radiation Therapy Effective in Treating Younger Men with Early-Stage Prostate Cancer
Monoclonal Antibodies to Help Locate and Treat Occult Metastases
NSAIDs May Prevent Colon Cancer Through Apoptosis, Not Anti-inflammatory Effects
New DNA Analysis Technique Superior in Determining Breast Cancer Prognosis, Says Study in JNCI
ABMT Recommended for Relapsed Hodgkin's Disease, But Better Overall Survival Not Yet Proved
Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
5 experts in this video
Related Content
Advertisement

The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

Russ Conroy
May 7th 2025
Article

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.


Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.


CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Tim Cortese
April 25th 2025
Article

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.


A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.


Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

Roman Fabbricatore
April 17th 2025
Article

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.


Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

Tim Cortese
April 16th 2025
Article

At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.

Related Content
Advertisement

The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

Russ Conroy
May 7th 2025
Article

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.


Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.


CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Tim Cortese
April 25th 2025
Article

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.


A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.


Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

Roman Fabbricatore
April 17th 2025
Article

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.


Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

Tim Cortese
April 16th 2025
Article

At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.